Website intended for a NZ health professional readership
Psychiatrist David Codyre reviews the growing evidence for low-dose naltrexone in the treatment of functional syndromes such as fibromyalgia, chronic fatigue and long COVID
1. Toljan K, Vrooman B. Low-dose naltrexone (LDN) – review of therapeutic utilization. Med Sci (Basel) 2018;6(4):82.
2. Hatfield E, Phillips K, Swidan S, et al Use of low-dose naltrexone in the management of chronic pain conditions: A systematic review. J Am Dent Assoc 2020;151(12):891–902.e1.
3. Lie MRKL, van der Giessen J, Fuhler GM, et al. Low dose naltrexone for induction of remission in inflammatory bowel disease patients. J Transl Med 2018;16(1):55.
4. O’Kelly B, Vidal L, McHugh T, et al. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health 2022;24:100485.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
